



Supernus Pharmaceuticals, Inc.  
Investor Relations Department  
1550 East Gude Drive  
Rockville, MD 20850  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: SUPN**

Last Trade:	41.85
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	-0.75  (-1.761%)
Day Range	41.80 - 43.25
52-Week Range	17.25 - 50.05
Volume	421,091

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Supernus Pharmaceuticals extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.

... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

- Sep 18, 2017  
[Supernus Provides Update on SPN-810 Phase III Clinical Trials](#)
- Aug 15, 2017  
[Supernus Defeats Second Generic Challenger to Oxtellar XR®](#)
- Aug 2, 2017  
[Supernus Announces Record Second Quarter 2017 Financial Results](#)
- Jul 19, 2017  
[Supernus to Host Second Quarter 2017 Earnings Conference Call](#)
- Jun 21, 2017  
[Supernus Announces that its Partner Shire Receives FDA Approval for Mydayis™ for ADHD](#)

## Financials & Filings [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 16, 2017  
[Annual Report \(10-K\)](#)
- Apr 27, 2017  
[Proxy Statement \(DEF 14A\)](#)
- Aug 3, 2017  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017  
[Quarterly Report \(10-Q\)](#)
- Jan 20, 2017  
[Quarterly Report \(10-Q\)](#)